跳至主要内容
临床试验/NCT04698616
NCT04698616Unknown不适用

The Relation Between Lean Body Mass and Side Effects Induced by Chemotherapy in Patients With Lymphoma: A Prospective Cohort Study

Jens Rikardt Andersen2 个研究点 分布在 1 个国家目标入组 141 人开始时间: 2020年2月9日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
141
试验地点
2
主要终点
Lean Body Mass (LBM)

研究概览

简要总结

The primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (LBM) and the development of side effects induced by chemotherapy in patients with lymphoma. Secondarily, the maximum tolerable dose of chemotherapeutics (MTD), patients' quality of life (QOL), nutritional status and physical activity during the course of treatment are estimated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients receiving myelosuppressive treatment for malignant lymphoma assessed by the investigator.
  • Legal of age

排除标准

  • ECOG Performance Status ≥2
  • People who cannot speak and understand Danish
  • Pregnant and breastfeeding

结局指标

主要结局

Lean Body Mass (LBM)

时间窗: 8 weeks (two treatment cycles)

LBM measured by bioelectrical impedans corelated to the dosis of chemotherapeutics given

次要结局

  • Quality of life (QOL) (score EORTC)(8 weeks (two treatment cycles))
  • Maximal tolerable dose of chemotherapeutics (microg/ml/kg LBM),(8 weeks (two treatment cycles))
  • nutritional status at inclusion (NRS2002 - scale)(8 weeks (two treatment cycles))
  • physical activity (scale - questionaire)(8 weeks (two treatmenr cycles))

研究者

发起方
Jens Rikardt Andersen
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jens Rikardt Andersen

Sponsor - Investigator

University of Copenhagen

研究点 (2)

Loading locations...

相似试验